Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURANEST vs ARESTOCAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Induction of general anesthesia,Supplementation of subpotent anesthetic agents (off-label),Procedural sedation (off-label)
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Primarily hepatic via hydrolysis by esterases (plasma and hepatic) to inactive metabolites. Less than 5% excreted unchanged in urine.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
85-90% bound primarily to alpha-1-acid glycoprotein; minor binding to albumin.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Vd is 2.5-3.5 L/kg, indicating extensive extravascular distribution and tissue binding.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Oral: 60-70% (first-pass metabolism); Intramuscular: ~90%; Intravenous: 100%.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
No specific guidelines; contraindicated in severe renal impairment due to potential for accumulation of preservatives.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Use with caution; no specific Child-Pugh adjustments available. Contraindicated in severe hepatic disease due to impaired metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended for pediatric use due to limited data and high risk of neurotoxicity.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
Reduce dose and volume; monitor for prolonged motor block and hypotension. Use lowest effective dose.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
None.
There is no FDA black box warning for Arestocaine hydrochloride.
Adrenocortical suppression: Etonidate inhibits 11β-hydroxylase, reducing cortisol and aldosterone synthesis; may last up to 24 hours after single dose.,Myoclonus: Involuntary muscle movements occur in up to 70% of patients, especially with rapid injection.,Hypotension: Less pronounced than with other induction agents, but may occur, particularly in hypovolemic patients.,Injection site pain: Common with peripheral administration.,Use in intensive care: Prolonged infusion associated with increased mortality; not recommended for sedation in ICU.,Pregnancy category C: Use only if clearly needed.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to etonidate or any component of the formulation,Use as sole anesthetic agent for major surgery without adequate muscle relaxation or intubation,Acute porphyria (relative contraindication)
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
No known direct food interactions. However, avoid hot beverages and foods until numbness resolves to prevent oral burns. No specific dietary restrictions.
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only if clearly needed. Second and third trimesters: no known teratogenic risk; may cause fetal bradycardia if high systemic levels occur. Avoid in near-term unless necessary due to neonatal effects.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Excreted in breast milk in low concentrations; M/P ratio not established. Expected milk levels are minimal after regional anesthesia. Use with caution; monitor infant for signs of local anesthetic toxicity (irritability, drowsiness). Instruct mother to discard milk for 4 hours after injection if concerned.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
No standard dose adjustments required for pregnancy per se. However, due to increased epidural venous plexus engorgement and decreased volume of distribution in the epidural space, reduce dose by 20-30% for epidural anesthesia to avoid unintended high block. Use lowest effective dose to minimize maternal and fetal exposure.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
DURANEST (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) is an amide local anesthetic commonly used in dentistry. Not effective for topical anesthesia; must be injected. Onset is rapid (1-3 min) with duration of pulpal anesthesia ~60-75 min and soft tissue anesthesia ~2-4 h. Maximum dose: 7 mg/kg (epinephrine 1:100,000) or 5 mg/kg (epinephrine 1:200,000). Avoid in patients with sulfite allergy (epinephrine component) or para-aminobenzoic acid (PABA) hypersensitivity. Caution in patients with methemoglobinemia (can cause methemoglobin formation at high doses).
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Avoid eating or drinking until numbness in mouth and throat has fully resolved (usually 2-4 hours) to prevent accidental biting or burns.,Do not chew gum or eat hard foods while numb.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or prolonged numbness (>8 hours) to your dentist immediately.,Inform your dentist of all medications you are taking, especially MAO inhibitors, tricyclic antidepressants, beta-blockers, and anticoagulants.,If you have a history of sulfite sensitivity, tell your dentist before the procedure.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURANEST vs ARESTOCAINE HYDROCHLORIDE, answered by our medical review team.
DURANEST is a Local Anesthetic that works by Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.. ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURANEST and ARESTOCAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURANEST is: 2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURANEST and ARESTOCAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURANEST is classified as Category C. Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only i. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.